Navigation Links
Nabriva Therapeutics Appoints Dr Colin Broom as Chief Executive Officer

VIENNA, September 3, 2014 /PRNewswire/ --

New US Subsidiary to be located in the Philadelphia Area 

Nabriva Therapeutics AG, a biotechnology company focused on developing pleuromutilins, a new class of antibiotics for the treatment of serious infections caused by resistant gram-positive and gram-negative pathogens, today announced the appointment of Dr Colin Broom as Chief Executive Officer (CEO). Current CEO Ralf Schmid will remain a member of the executive management team and move to the role of Chief Operating Officer (COO) and Chief Financial Officer (CFO). The company also announced the establishment of a US subsidiary, based in Philadelphia, Pennsylvania, where the clinical development team will be located. All other activities will remain in Vienna. Nabriva plans to take its lead product lefamulin (BC‑3781) into late stage development in community-acquired bacterial pneumonia and advance its pipeline of Extended Spectrum Pleuromutilins (ESP), active against gram-negative bacteria.

Dr Denise Pollard-Knight, Chairman of the Supervisory Board of Nabriva, commented on the appointment: "We welcome Colin to Nabriva and are delighted to announce the opening of our US subsidiary. Colin's track record and experience will enable us to maximise the potential in Nabriva's pipeline. The increasing interest in the development of new antibiotics and a favourable funding environment for biotech companies in the US provide a great opportunity to position the company for significant growth in the future.

"I would like to take this opportunity to thank Ralf Schmid, the current CEO who is assuming the roles of COO and CFO. Ralf has been instrumental in establishing Nabriva and leading us to this important stage, and will in his new role head the Austrian site and continue to play a key role in the company's future development."

Dr Broom, newly appointed Chief Executive Officer of Nabriva, added: "New antibiotic development is one of the most important priorities in medicine as we see increasing resistance to currently available drugs.  Nabriva is one of a few development stage companies with a truly novel antibiotic product ready for phase 3 studies in an area of significant unmet medical need, and with a clear development path to potential approval. I am very excited to join Nabriva at this stage and look forward to working with the highly experienced board and management team on building a patient-centric global biopharmaceutical company. My immediate attention is focussed on establishing a world-class clinical development team in the Philadelphia area."

Dr Broom has worked in biopharmaceutical drug development and commercialization for 30 years. Most recently he served as Chief Scientific Officer at ViroPharma, Inc., which was acquired by Shire plc for $4.2bn in January 2014. Prior development roles included senior positions at Amgen, Hoechst Marion Roussel (now Sanofi), SmithKline Beecham and Glaxo (now GlaxoSmithKline). Dr Broom also serves on the board of NPS Pharmaceuticals.

Dr Broom holds a Bachelor of Science degree in pharmacology from University College, London, and a Bachelor of Medicine and Bachelor of Surgery degree from St. George's Hospital Medical School, London. He is a Member of the Royal College of Physicians and a Fellow of the Faculty of Pharmaceutical Medicine of the UK Colleges of Physicians.

Notes to editors 

About Nabriva Therapeutics AG  

Nabriva Therapeutics is a biotechnology company focused on developing a new class of antibiotics, the pleuromutilins, for the treatment of patients with serious infections caused by multi-drug resistant pathogens. Nabriva's world-class medicinal chemistry expertise has achieved an industry first with the development of both intravenously administered and orally available pleuromutilins that are therefore ideal for i.v. to oral switch therapy.

Nabriva's lead product lefamulin (BC‑3781) is about to enter Phase 3 clinical studies. Due to its broad spectrum, oral and i.v. formulations, and a favourable safety profile, lefamulin is the first of a new class of antibiotics ideally positioned for the treatment of community-acquired bacterial pneumonia (CABP), plus hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP), as well as acute bacterial skin and skin structure infections (ABSSSI), with potential in several other indications (sexually transmitted infections including MDR gonorrhoea; osteomyelitis) including paediatric use.

Nabriva's preclinical program, the Extended Spectrum Pleuromutilins (ESPs) expands the activity of pleuromutilins to include major enteric Gram-negative pathogens such as E. coli and K. pneumoniae. The targeted indications for the ESP extend beyond the current use of the first-generation pleuromutilins, thereby filling important gaps in treatment options of both marketed antibiotics and compounds in development.

For further information, please contact: 

Nabriva Therapeutics AG
Dr Colin Broom, Chief Executive Officer
Tel: +43(0)1-740-930

Hume Brophy
Mary Clark, Supriya Mathur, Hollie Vile
Tel: +44(0)2034405654


SOURCE Nabriva Therapeutics AG
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
Post Your Comments:
(Date:12/1/2015)... Sverige, December 1, 2015 ... Cancer Study Group (IBCSG, Bern ... ingå i en klinisk studie av palbociclib, ett ... --> Studien, med namn PYTHIA, kommer ... anti-hormonella läkemedel i kombination med palbociclib, som tillhör ...
(Date:11/30/2015)... , Dec. 1, 2015 Researchers have developed ... body part thickness and checks for motion, positioning and ... feasibility study presented today at the annual meeting of ... (RSNA). Steven Don , M.D., associate ... University School of Medicine in St. Louis, ...
(Date:11/30/2015)... Die MEDTEC Japan 2016, ... Entwicklung und Herstellung medizinischer Geräte, findet ... in Tokyo ... Foto: ... --> ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... December 01, 2015 , ... ... as a 2015-2016 inductee into its VIP Woman of the Year Circle. ... the nation’s leading networking organization exclusively for professional women, boasting 850,000 members and ...
(Date:11/30/2015)... (PRWEB) , ... December 01, 2015 , ... ... Dale Jones as a 2015-2016 inductee into its VIP Woman of ... education. NAPW is the nation’s leading networking organization exclusively for professional women, boasting ...
(Date:11/30/2015)... , ... December 01, 2015 , ... ... latest carrier to offer individual vision insurance plans on . The ... ability to rate and review products, allowing consumers to compare, quote and match ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... Until now, ... criteria set forth in the MOMS (Management of Myelomeningocele Study) trial. One of these ... Control and Prevention), a BMI of 18.5 to 24.9 is considered normal, 25 - ...
(Date:11/30/2015)... ... November 30, 2015 , ... Stress, anxiety, illness, infection or ... worry about possible tumors? , Heather Spader, MD, a new pediatric neurosurgeon at Joe ... some signs might point to tumors. , “Bad headaches that don’t go ...
Breaking Medicine News(10 mins):